ClinicalTrials.gg
CompletedNCT06422104Updated Apr 13, 2026Results posted

Neuromodulation Therapy for Task-Specific Dystonia

An interventional study of Repetitive transcranial magnetic stimulation in Isolated Focal Hand Dystonia, sponsored by Duke University. Completed at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-04-13.

Sponsored by Duke University · Not applicable, Interventional, and Basic science

How we know

From the registry’s dates

  • Registered 5 years 8 months after the study started (first participant enrolled Aug 2018, registered Apr 2024).

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
12
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 21 studies in Dystonia, Focal, Task-Specific with a site in United States — 1 open to participants now, 3 under way, none of them phase 3. Dystonia, Focal, Task-Specific · United States.

Started
2018
with 1 other
No phase
3 of 21
1 open now
Registered
21st of 21
by date
Lead sponsor
2 of 21
Duke University

Among the 21 studies in Dystonia, Focal, Task-Specific with a site in United States, this one is one of 2 that started in 2018, is one of 3 with no phase, and was the 21st registered.

Dystonia, Focal, Task-Specific

26 studies on the registry are indexed under Dystonia, Focal, Task-Specific; 3 are open to participants now.

Browse Dystonia, Focal, Task-Specific studies →

Open to participants now

1 of the 21 studies in Dystonia, Focal, Task-Specific with a site in United States is open now. Recruiting first, the newest first:

A study can be open while its sites in United States have not opened yet or have stopped. Only those recruiting at a site in United States →

Who these studies take

Of the 2 Dystonia, Focal, Task-Specific studies recruiting now, 1 sets no upper age limit and 1 stops at 75 or younger; none take children under 18; none take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 21 studies in Dystonia, Focal, Task-Specific with a site in United States, or all of them as a file.
02

Study summary

This study aims to apply a non-invasive brain stimulation technology called repetitive Transcranial Magnetic Stimulation (rTMS) in patients with focal hand dystonia (FHD). The goal of the study is to identify which cortical target (premotor cortex (PMC) or primary somatosensory cortex (PSC)) will show benefit after active rTMS compared to sham rTMS. A secondary goal of the study is to understand if 10 Hz rTMS can show behavioral benefit compared to sham rTMS. The study will evaluate rTMS response using measures if writing on a sensor tablet, examiner and patient dystonia rating scales and brain imaging scan (functional MRI) to understand brain changes after rTMS. Safety measures include adherence to TMS guidelines and thorough medical screening to prevent seizures.

Read the detailed description

The primary objective of this study is to develop rTMS for FHD. The focus is to assess whether stimulating the PMC or PSC will show greater improvement in writing behavior. This research builds upon prior studies that have demonstrated improvement in behavior after rTMS to PMC and PSC. The study includes five sequential visits:

  • Visit 1 behavior writing measures and dystonia rating scales.
  • Visit 2 includes task-based functional MRI brain scans to develop cortical target for rTMS sessions.
  • Visits 3, 4, and 5: FHD participants receive 10 Hz rTMS to PMC, PSC and sham rTMS to PMC in a cross over design with at minimum one week of washout between sessions. Participants complete behavior writing measures and rating scales on same day before and after each TMS session and an fMRI after each TMS session. Up to 5 Healthy Volunteers were recruited to help develop the TMS visits.

The information in this record reflects Visits 3-5

03

Conditions studied

  • Isolated Focal Hand Dystonia
04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • Healthy Control Participants:

    1. 18yrs and older
    2. Left or Right hand dominance
    3. Age-matched to Focal Hand dystonia patients
    4. Must be able to sign
    5. Must be literate
  • Focal Hand dystonia Patients:

    1. 18yrs and older
    2. Left or Right hand dominance
    3. Diagnosed with Writer's Cramp dystonia in left or right hand
    4. Must be able to sign informed consent
    5. Must be literate

Exclusion criteria

Exclusion Criteria:

Healthy Control Participants (visits 2, 3, 4, and 5) and Focal Hand dystonia Patients (visits 2, 3, 4, and 5):

  1. Other neurological movement disorders diagnoses including other types of dystonia, Parkinsonism, or essential tremor
  2. Botulinum toxin injections within 3 months of research study
  3. Medications with effects on the central nervous system including anticholinergic, benzodiazepines, and muscle relaxants among others within 1 week of the study
  4. No physical or occupational therapy of the upper extremities
  5. Any to MRI (ie: metal in body or implanted medical devices, etc)
  6. Any contraindication on TMS adult safety screening (TASS form) including seizure history, pregnancy, brain injury, cranial metal implants, known structural brain lesion
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

Contraindication

A reason a treatment, test or procedure should not be given to a particular person, such as an allergy, another illness or a medicine they take.

05

Study design

Phase
Not applicable
Primary purpose
Basic science
Allocation
Randomized
Intervention model
Crossover assignment
Masking
Double (Participant, Outcomes assessor)
Enrollment
12 participants (actual)

Study arms

  • Active comparator
    10 Hz rTMS to premotor cortex

    10 Hz rTMS to premotor cortex

    Device: Repetitive transcranial magnetic stimulation

  • Active comparator
    10 Hz rTMS to primary somatosensory cortex

    10 Hz rTMS to primary somatosensory cortex

    Device: Repetitive transcranial magnetic stimulation

  • Active comparator
    0.7 Hz rTMS to premotor cortex

    0.7 Hz rTMS to premotor cortex

    Device: Repetitive transcranial magnetic stimulation

Interventions

  • DeviceRepetitive transcranial magnetic stimulation

    10 Hz repetitive TMS will be delivered for 20 minutes per session and 0.7 Hz for 20 minutes per session

06

What researchers measure

Primary outcomes

  1. Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions

    Time frame: Pre-TMS and post-TMS session (each session is approximately 45 minutes)

Secondary outcomes

  1. Safety, as Measured by TMS Acute Side Effects

    Time frame: During TMS session (each session is approximately 45 minutes)

  2. Change in Peak Accelerations Behavior (Calculated by Taking the Change in Peak Accelerations From Behavior Performed Before and After Each TMS Visit).

    Change in peak accelerations behaviors pre- and post-TMS is calculated by taking the change in peak accelerations from behavior performed before and after each TMS visit. Higher measures of peak accelerations represent greater writing dysfluency and worsening dystonia.

    Time frame: Pre-TMS and post-TMS session (each session is approximately 45 minutes)

  3. Brain Connectivity Between Superior Parietal Cortex to Right Cerebellum VIII

    Brain connectivity was assessed using functional magnetic resonance imaging of the brain. The z-score is mathematical calculation of the synchronization between brain regions. Specifically, functional connectivity z-scores quantify the strength of synchronization between brain regions by transforming Pearson correlation coefficients (r-values) into normally distributed values (z-scores). This Fisher-z transformation stabilizes variance, enabling valid group-level statistical comparisons (e.g., t-tests) of functional connectivity. Positive Z-scores (Z scores\> 0) represent stronger synchronization between brain regions and strengthening of connectivity between brain regions; negative Z-scores (Z-scores \<0) indicate anti-synchronization between brain regions and weakening of connectivity between brain regions.

    Time frame: Post-TMS session (each session is approximately 45 minutes)

07

Results

Posted Apr 13, 2026

Participant flow

First TMS Visit (1 Day)
Participant flow — First TMS Visit (1 Day)
MilestonePMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMC
Started222222
Completed222222
Not completed000000
Washout (1 Week)
Participant flow — Washout (1 Week)
MilestonePMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMC
Started222222
Completed222222
Not completed000000
Second TMS Visit (1 Day)
Participant flow — Second TMS Visit (1 Day)
MilestonePMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMC
Started222222
Completed222222
Not completed000000
Washout (1 Week)
Participant flow — Washout (1 Week)
MilestonePMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMC
Started222222
Completed222222
Not completed000000
Third TMS Visit (1 Day)
Participant flow — Third TMS Visit (1 Day)
MilestonePMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMC
Started222222
Completed222222
Not completed000000

Outcome measures

PrimaryFeasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions
Time frame:
Pre-TMS and post-TMS session (each session is approximately 45 minutes)
Reported as:
Count of participants · Participants
Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions
ParticipantsrTMS to Premotor Cortex (PMC)rTMS to Primary Somatosensory Cortex (PSC)Sham rTMS
Feasibility of Accurately Delivering TMS During the Task of Writing as Measured by Number of Participants Who Completed the TMS Sessions121211
SecondarySafety, as Measured by TMS Acute Side Effects
Time frame:
During TMS session (each session is approximately 45 minutes)
Reported as:
Number · acute side affects
Safety, as Measured by TMS Acute Side Effects
acute side affects10 Hz rTMS to Premotor Cortex10 Hz rTMS to Primary Somatosensory CortexSham TMS
Safety, as Measured by TMS Acute Side Effects000
SecondaryChange in Peak Accelerations Behavior (Calculated by Taking the Change in Peak Accelerations From Behavior Performed Before and After Each TMS Visit).

Change in peak accelerations behaviors pre- and post-TMS is calculated by taking the change in peak accelerations from behavior performed before and after each TMS visit. Higher measures of peak accelerations represent greater writing dysfluency and worsening dystonia.

Time frame:
Pre-TMS and post-TMS session (each session is approximately 45 minutes)
Reported as:
Mean · percentage of pre-TMS session
Change in Peak Accelerations Behavior (Calculated by Taking the Change in Peak Accelerations From Behavior Performed Before and After Each TMS Visit).
percentage of pre-TMS session10 Hz rTMS to Premotor Cortex10 Hz rTMS to Primary Somatosensory CortexSham TMS
Change in Peak Accelerations Behavior (Calculated by Taking the Change in Peak Accelerations From Behavior Performed Before and After Each TMS Visit).99.00 ± 0.9096.43 ± 1.39100.06 ± 0.76
Statistical analysis
  • 10 Hz rTMS to Primary Somatosensory Cortex vs Sham TMS · Mixed Effects Model for Repeated Measure · p = 0.001
  • 10 Hz rTMS to Premotor Cortex vs 10 Hz rTMS to Primary Somatosensory Cortex · Mixed Effects Model for Repeated Measure · p = 0.012
SecondaryBrain Connectivity Between Superior Parietal Cortex to Right Cerebellum VIII

Brain connectivity was assessed using functional magnetic resonance imaging of the brain. The z-score is mathematical calculation of the synchronization between brain regions. Specifically, functional connectivity z-scores quantify the strength of synchronization between brain regions by transforming Pearson correlation coefficients (r-values) into normally distributed values (z-scores). This Fisher-z transformation stabilizes variance, enabling valid group-level statistical comparisons (e.g., t-tests) of functional connectivity. Positive Z-scores (Z scores\> 0) represent stronger synchronization between brain regions and strengthening of connectivity between brain regions; negative Z-scores (Z-scores \<0) indicate anti-synchronization between brain regions and weakening of connectivity between brain regions.

Time frame:
Post-TMS session (each session is approximately 45 minutes)
Reported as:
Mean · z-score
Brain Connectivity Between Superior Parietal Cortex to Right Cerebellum VIII
z-score10 Hz rTMS to Premotor Cortex10 Hz rTMS to Primary Somatosensory CortexSham TMS
Brain Connectivity Between Superior Parietal Cortex to Right Cerebellum VIII0.28 ± 0.030.27 ± 0.040.44 ± 0.03
Statistical analysis
  • 10 Hz rTMS to Primary Somatosensory Cortex vs Sham TMS · Mixed-effects Model for Repeated Measure · p = 0.048

Adverse events

Collected over The standard TMS adverse events survey was collected before and after each TMS session. Each session lasted about 45 minutes.. Non-serious events are listed at a 0% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
rTMS to Premotor Cortex (PMC)0/12 (0%)0/12 (0%)0/12 (0%)
rTMS to Primary Somatosensory Cortex (PSC)0/12 (0%)0/12 (0%)0/12 (0%)
Sham rTMS0/12 (0%)0/12 (0%)0/12 (0%)

Baseline characteristics

Age, Categorical
Age, Categorical(Participants)PMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMCTotal
<=18 years0000000
Between 18 and 65 years2201229
>=65 years0021003
Sex: Female, Male
Sex: Female, Male(Participants)PMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMCTotal
Female0000011
Male22222111
Ethnicity (NIH/OMB)
Ethnicity (NIH/OMB)(Participants)PMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMCTotal
Hispanic or Latino1000001
Not Hispanic or Latino12222211
Unknown or Not Reported0000000
Race (NIH/OMB)
Race (NIH/OMB)(Participants)PMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMCTotal
American Indian or Alaska Native0000000
Asian0000000
Native Hawaiian or Other Pacific Islander0000000
Black or African American0000000
White22222212
More than one race0000000
Unknown or Not Reported0000000
Region of Enrollment
Region of Enrollment(participants)PMC, PSC, ShamPMC, Sham, PSCPSC, PMC, ShamSham, PMC, PSCPSC, Sham, PMCSham, PSC, PMCTotal
United States22222212
08

Study locations

1 site
  • Duke University Health System
    Durham, North Carolina 27705, United States
09

References and documents

Publications

  • Mulcahey PJ, Peterchev AV, Calakos N, Bukhari-Parlakturk N. Transcranial magnetic stimulation: the road to clinical therapy for dystonia. Dystonia. 2023 August; 2.
  • Bukhari-Parlakturk N, Mulcahey PJ, Lutz M, Ghazi R, Huang Z, Dannhauer M, Simsek Z, Groves S, Lipp M, Fei M, Tran T, Wood E, Beynel L, Scott B, Termsarasab P, Petty C, Al-Khalidi HR, Voyvodic J, Appelbaum LG, Davis S, Michael A, Peterchev AV, Calakos N. Functional MRI-guided personalized TMS decreases basal ganglia activity and improves focal hand dystonia. International Organization of Human Brain Mapping Conference. Montreal, Canada. July 22-26, 2023. virtual poster presentation.
  • Bukhari-Parlakturk N, Mulcahey PJ, Lutz M, Ghazi R, Huang Z, Dannhauer M, Simsek Z, Groves S, Lipp M, Fei M, Tran T, Wood E, Beynel L, Scott B, Termsarasab P, Petty C, Al-Khalidi HR, Voyvodic J, Appelbaum LG, Davis S, Michael A, Peterchev AV, Calakos N. Functional MRI-guided personalized TMS decreases basal ganglia activity and improves focal hand dystonia. International Dystonia Symposium. Dublin, Ireland. June 1-3, 2023. poster presentation.
  • Bukhari-Parlakturk N, Lutz MW, Al-Khalidi HR, Unnithan S, Wang JE, Scott B, Termsarasab P, Appelbaum LG, Calakos N. Suitability of Automated Writing Measures for Clinical Trial Outcome in Writer's Cramp. Mov Disord. 2023 Jan;38(1):123-132. doi: 10.1002/mds.29237. Epub 2022 Oct 13. PubMed 36226903 ↗
  • Dannhauer M, Huang Z, Beynel L, Wood E, Bukhari-Parlakturk N, Peterchev AV. TAP: targeting and analysis pipeline for optimization and verification of coil placement in transcranial magnetic stimulation. J Neural Eng. 2022 Apr 21;19(2):10.1088/1741-2552/ac63a4. doi: 10.1088/1741-2552/ac63a4. PubMed 35377345 ↗
  • Bukhari-Parlakturk N, Mulcahey PJ, Lutz MW, Ghazi R, Huang Z, Dannhauer M, Termsarasab P, Scott B, Simsek ZB, Groves S, Lipp M, Fei M, Tran TK, Wood E, Beynel L, Petty C, Voyvodic JT, Appelbaum LG, Al-Khalidi HR, Davis SW, Michael AM, Peterchev AV, Calakos N. Motor network reorganization associated with rTMS-induced writing improvement in writer's cramp dystonia. Brain Stimul. 2025 Mar-Apr;18(2):198-210. doi: 10.1016/j.brs.2025.02.005. Epub 2025 Feb 7. PubMed 39924101 ↗

Study documents

PDFs hosted by the registry, ClinicalTrials.gov.

Individual participant data

Plan to share: No

10

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Ran from Aug 2018 to primary completion in Jan 2023, 52 months.

Results were first posted in Apr 2026, 3 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Apr 24, 2024
First posted
May 20, 2024
StartActual
Aug 23, 2018
Primary completionActual
Jan 13, 2023
CompletionActual
Jan 13, 2023
Results first posted
Apr 13, 2026
Last update
Apr 13, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Apr 13, 2026, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
11

Registry details

Key details

Study ID
NCT06422104
Lead sponsor
Duke University
Collaborators
Doris Duke Charitable Foundation, Dystonia Coalition, Dystonia Study Group, National Center for Advancing Translational Sciences (NCATS)
Responsible party
Sponsor
First posted
May 20, 2024
Start date
Aug 23, 2018
Primary completion
Jan 13, 2023
Completion
Jan 13, 2023
Results posted
Apr 13, 2026
Last update
Apr 13, 2026

Study contacts

Noreen Bukhari-Parlakturk, MD PhD
principal investigator · Duke Health

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
Yes
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in May 2024. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion